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Abstract Although anxiety disorders and headaches are
comorbid conditions, there have been no studies evaluating
the prevalence of primary headaches in patients with gen-
eralizedanxietydisorder(GAD).Theaimofthisstudywasto
analyze the lifetime prevalence of primary headaches in
individuals with and without GAD. A total of 60 individuals
were evaluated: 30 GAD patients and 30 controls without
mental disorders. Psychiatric assessments and primary
headache diagnoses were made using structured interviews.
Among the GAD patients, the most common diagnosis was
migraine,whichwassigniﬁcantlymoreprevalentamongthe
GAD patients than among the controls, as were episodic
migraine, chronic daily headache and aura. Tension-type
headache was equally common in both groups. Primary
headaches in general were signiﬁcantly more common and
more severe in GAD patients than in controls. In anxiety
disorder patients, particularly those with GAD, accurate
diagnosis of primary headache can improve patient man-
agement and clinical outcomes.
Keywords Migraine  Anxiety disorders 
Generalized anxiety disorder  Comorbidity
Introduction
Migraine is a common and debilitating chronic neuro-
logical illness [1], the lifetime prevalence rates of which
are 12–22% in women and 4–10% in men [2]. The
prevalence of chronic migraine in the general population
ranges from 2 to 3% [3–5]. At tertiary-care headache
centers, up to 60% of all consultations are for migraine
[6]. In the management of patients with chronic
migraine, comorbidity is an important issue. A common
comorbidity is anxiety, which is found in up to 75% of
cases [7].
The Epidemiologic Catchment Area Study conducted by
the United States National Institute of Mental Health from
1980 to 1984, involved 18,500 adults in 5 communities.
That study, which provided the most consistent epidemi-
ologic data currently available, demonstrated that anxiety
disorders were the most prevalent mental disorders in the
general population. Subsequently, the National Comor-
bidity Survey, conducted in 1990, showed that the lifetime
prevalence of anxiety disorder was 24% [8]. In clinical
settings, the most common anxiety disorder is generalized
anxiety disorder (GAD). In the general population, the
lifetime prevalence of GAD is 3.1%, whereas the 12-month
prevalence is 5.1% [8].
A high level of disability, a low level of life satisfaction
and an impaired quality of life have often been associated
with GAD [9], which is also the anxiety disorder most
often associated with migraine [10, 11].
To date, there have been no studies using standardized,
validated methods of assessing psychiatric diagnosis and
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primary headaches in patients with GAD.
Merikangas et al. [11] found GAD incidence to be ﬁve
times higher in migraineurs (9.8%) than in nonmigraineurs
(2.0%). Similar results were obtained for social phobia,
which was diagnosed in 6.6% of the migraineurs and 2.0%
of the nonmigraineurs. Breslau et al. [12] also found GAD
prevalence to be higher among migraine patients than
among controls. Anxiety disorders, including phobia, panic
disorder, GAD and obsessive–compulsive disorder, were
found to be strongly associated with migraine. Both studies
[11, 12], however, had methodological limitations; head-
ache diagnosis was not conﬁrmed by a headache specialist,
and most of the mental health clinical data was ﬁlled out by
patients.
In the present study, we analyzed the prevalence of
primary headaches in GAD patients.
Methods
Patients with GAD were recruited from among those vol-
untarily enrolled in the Anxiety Disorders Program of the
Institute of Psychiatry, operating out of the University of
Sao Paulo School of Medicine Hospital das Clı ´nicas, where
the study was performed. Thirty patients diagnosed with
GAD, according to the Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition (DSM-IV), were
included in the study; 7 (23.3%) were males, and 23
(76.6%) were females. The mean age of the GAD patients
was 42.6 ± 12.2 years (range 19–64 years).
Thirty-two control subjects without mental disorders,
participants of an earlier study [13], were submitted to a
clinical interview with the author, and 30 were included in
the study; 14 (46.6%) were males, and 16 (53.3%) were
females. The mean age of the controls was 39.5 ±
11.2 years (range 23–70 years).
All patients were carefully interviewed for psychiatric
assessment, using a standardized, validated psychiatric
diagnostic method, the Structured Clinical Interview for
DSM-IV Axis I Disorders, Patient Edition (SCID-1/P) [14],
which was applied by a psychologist with extensive
training in clinical psychiatry. Primary headaches were
diagnosed according to the criteria established in the Sec-
ond Edition of International Classiﬁcation of Headache
Disorders (ICHD-II), using a structured interview [15].
All of the patients underwent a clinical interview in
order to collect data related to demographics, anthropo-
metrics, headache features, analgesic consumption and
psychiatric comorbidities, as well as medical and social
consequences. Patient demographic data included gender,
age, education level, marital status and employment status.
The anthropometric data collected were weight, height and
body mass index. In terms of headache-related variables,
the lifetime prevalence of primary headaches was evalu-
ated, as was the intensity, duration, frequency and age of
onset of headache symptoms. In addition, use of analgesics
and consumption of caffeine were quantiﬁed. Symptoms
were evaluated using the following instruments: the
Hamilton Anxiety Rating Scale [16]; the Hamilton
Depression Rating Scale [17]; the Fatigue Severity Scale
[18]; the Chalder Fatigue Scale [19]; the Visual Analog
Scale for Fatigue [20]; and the Epworth Sleepiness Scale
[21]. Headache intensity was scored on a scale from 0 to
10. Medical and social consequences, such as headache
disability, use of health services and quality of life, were
analyzed using the Migraine Disability Assessment ques-
tionnaire [22] and the Medical Outcome Study 36-Item
Short-Form Health Survey (SF-36) [23].
During the standardized SCID interview, questions
regarding the onset of GAD symptoms and the onset of
headache symptoms were posed by a single interviewer.
The responses to the latter set of questions were conﬁrmed
by a neurologist. Only responses in which patients and
researchers both presented a signiﬁcant degree of conﬁ-
dence were included in the analysis. All clinical measures
were rated by clinicians and not patients.
Patients presenting medical conditions, mental disorders
or situations that might place the patient at signiﬁcant risk,
interfere with results or substantially affect patient partic-
ipation were excluded.
The study protocol complied with Good Clinical Prac-
tice principles and the Helsinki Declaration, and the study
design was approved by the local research ethics commit-
tees of the institutions involved. All patients gave written
informed consent.
The SAS statistical package, version 8.2 (SAS Institute,
Cary, NC, USA), and the Minitab statistical package,
version 14 (Minitab Inc., State College, PA, USA), were
used for statistical analysis. The initial descriptive analysis
of variables included frequency, mean and standard devi-
ation. Quantitative data are expressed as mean ± standard
deviation. Proportions between two independent groups
were compared using the v
2 test or Fisher’s exact test when
appropriate. The Mann–Whitney nonparametric test was
used to compare variables between two independent
groups. Linear correlation analysis between two quantita-
tive variables was applied using Pearson’s correlation
coefﬁcient (r). Coefﬁcients ranged from -1 to 1 and were
rated low (for an r\0.4), moderate (for an r of 0.4–0.7) or
high (for an r[0.7). All signiﬁcance probabilities (P val-
ues) shown were two-tailed, and values of P\0.05 were
considered statistically signiﬁcant. Gender was not inclu-
ded in the statistical model, since, given the sample size,
we opted for a more conservative strategy involving non-
parametric analyses.
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Demographic data for GAD patients and controls are pre-
sented in Table 1. No signiﬁcant differences were found
between the two groups in terms of gender, age, level of
education, marital status or employment status.
As can be seen in Table 2, there were more women than
men in the GAD group. Although this difference was not
signiﬁcant, it might have skewed the results. However,
within the GAD group, there were no gender-related dif-
ferences in terms of the frequency of primary headaches,
headache or tension-type headache (TTH).
Anthropometric data for GAD patients and controls are
presented in Table 3. The two groups presented no sig-
niﬁcant differences in terms of weight, height or body mass
index.
Table 4 shows that the lifetime prevalence of primary
headaches was higher among GAD patients than among
controls (86.7 vs. 46.7%; P = 0.001; OR = 7.43; 95%
CI = 2.08–26.55). The frequency of migraine was also
higher among GAD patients than among controls (66.7 vs.
13.3%; P\0.001; OR = 13.00; 95% CI = 3.55–47.6),
episodic migraine (43.3 vs. 10%; P = 0.004; OR = 6.88;
95% CI = 1.71–27.75), chronic daily headache (20 vs. 0%;
P = 0.024) and aura (26.6 vs. 3.3%; P = 0.026;
OR = 10.55; 95% CI = 1.23–90.67). The prevalence of
TTH was comparable between the GAD group and the
control group (20 vs. 33.3%; P = 0.243).
Primary headache, migraine, episodic migraine and aura
exhibited stronger associations with the GAD group than
with the control group.
Headache characteristics are presented in Table 5. The
frequency of headaches was signiﬁcantly higher in GAD
patients than in controls (9.3 ± 9.5 vs. 2.0 ± 2.0 days per
month; P = 0.001), as was headache duration (20.9 ±
22.3 vs. 4.5 ± 7.6 h; P = 0.004) and headache intensity
(5.6 ± 2.2 vs. 3.9 ± 2.4; P = 0.049). For these variables,
there were no differences between the GAD and control
groups in terms of the proportions of men and women.
The GAD patients presented higher Hamilton Anxiety
Rating Scale scores than did the controls (22.1 ± 6.1 vs.
2.4 ± 2.4; P\0.001). Approximately 40% of the GAD
group patients reported moderate to severe anxiety, and
33.3% reported mild to moderate anxiety, whereas all of
the controls reported only mild anxiety (Table 6).
The GAD group patients presented higher Hamilton
Depression Rating Scale scores than did the controls
(13.7 ± 6.4 vs. 1.5 ± 2.5; P\0.001). Among the GAD
patients, mild depressive symptoms were reported by 60%,
moderate depressive symptoms by 16.7% and severe
depressive symptoms by 10%, whereas 90% of the controls
reported no depressive symptoms whatsoever (Table 6).
As can be seen in Table 6, the GAD patients scored
higher than did the controls on all three fatigue scales: the
Fatigue Severity Scale (47.6 ± 14.9 vs. 13.6 ± 14.9;
P\0.001); the Chalder Fatigue Scale (22.9 ± 7.2 vs.
3.5 ± 4.5; P\0.001); and the Visual Analog Scale for
Table 1 Demographic characteristics of the individuals studied
Characteristic GAD
(n = 30)
Controls
(n = 30)
P
Gender NS*
Male, n (%) 7 (23.3) 14 (46.6)
Female, n (%) 23 (76.6) 16 (53.3)
Age (years), mean ± SD
(range)
42.6 ± 12.2
(19–64)
39.5 ± 11.2
(23–70)
NS**
Education NS*
0–8 years, n (%) 10 (33.3) 7 (23.3)
9–11 years, n (%) 9 (30.0) 6 (20.0)
C12 years, n (%) 11 (36.7) 17 (56.7)
Employed, n (%) 27 (90) 26 (86.7) NS*
Marital status NS*
Married, n (%) 14 (46.7) 19 (63.3)
Unmarried, n (%) 16 (53.3) 11 (36.7)
Divorced, n (%) 3 (10) 3 (10)
Separated, n (%) 0 (0.0) 1 (3.3)
Widowed, n (%) 2 (6.7) 0 (0.0)
Single, n (%) 11 (36.7) 7 (23.3)
GAD generalized anxiety disorder (patients)
* v
2 test
** Mann–Whitney test
Table 2 Prevalence of primary headache, migraine and tension-type
headache in generalized anxiety disorder patients, by gender
Gender No primary
headache
Primary
headache
Total P
Male, n (%) 1 (14) 6 (86) 7 1.00*
Female, n (%) 3 (13) 20 (87) 23
Total 4 26
No migraine Migraine Total
Male, n (%) 3 (43) 4 (57) 7 0.858*
Female, n (%) 7 (30) 16 (70) 23
Total 10 20
No TTH TTH Total P
Male, n (%) 5 (71) 2 (29) 7 0.866*
Female, n (%) 19 (83) 4 (17) 23
Total 24 6
TTH Tension-type headache
* Mann–Whitney test
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123Fatigue (22.1 ± 31.6 vs. 15.0 ± 31.6; P\0.001). Fatigue
was diagnosed as signiﬁcantly incapacitating (Fatigue
Severity Scale score [27) in 63.3% of the GAD group
patients, compared with 3.3% of the controls (P = 0.001;
OR = 3.45). Table 6 also shows that there was no differ-
ence between GAD patients and controls in terms of the
mean score on the Epworth Sleepiness Scale (7.3 ± 6.7 vs.
4.2 ± 3.7; P = 0.118). Excessive daytime sleepiness
(Epworth Sleepiness Scale score C10) was diagnosed in
36.7% of the GAD group patients, compared with only
6.7% of controls (P = 0.004; OR = 2.13).
Table 7 shows that the Migraine Disability Assessment
score was signiﬁcantly higher for GAD patients with pri-
mary headaches than for controls with primary headaches
Table 3 Anthropometric data
Characteristic GAD (n = 30) Controls (n = 30) P
Weight (kg), mean ± SD 67.28 ± 14.58 71.57 ± 15.21 NS*
Height (m), mean ± SD 1.62 ± 0.09 1.70 ± 0.12 NS*
Body mass index (kg/m
2), mean ± SD 25.8 ± 5.7 24.4 ± 3.2 NS*
Body mass index C25, n (%) 14 (46.7) 14 (46.7) NS**
GAD generalized anxiety disorder (patients)
* Mann–Whitney test
** v
2 test
Table 4 Lifetime prevalence of primary headache
Headache type/subtype GAD, n (%) Controls, n (%) P OR 95% CI
Primary headache 26 (86.7) 14 (46.7) 0.001* 7.43 2.08–26.55
Migraine 20 (66.7) 4 (13.3) \0.001* 13.00 3.55–47.6
Episodic migraine 13 (43.3) 3 (10.0) 0.004* 6.88 1.71–27.75
Episodic migraine without aura 8 (26.7) 2 (6.6) 0.038* 5.09 0.98–26.43
Episodic migraine with aura 5 (16.6) 1 (3.3) NS** 5.8 0.63–53.01
Chronic migraine 5 (16.6) 0 (0.0) 0.052** 13.16 0.69–249.19
Chronic migraine without aura 2 (6.6) 0 (0.0) NS** 5.35 0.25–116.32
Chronic migraine with aura 3 (10) 0 (0.0) NS** 7.76 0.38–157.15
Probable migraine without aura 2 (6.6) 1 (3.3) NS** 2.07 0.18–24.15
Chronic daily headache 6 (20.0) 0 (0.0) 0.024** 16.18 0.87–301.64
TTH 6 (20.0) 10 (33.3) NS* 0.5 0.15–1.62
Infrequent episodic TTH 2 (6.6) 7 (23.3) NS** 0.23 0.04–1.24
Frequent episodic TTH 3 (10.0) 3 (10.0) NS* 1 0.19–5.4
Chronic TTH 1 (3.3) 0 (0.0) NS** 3.1 0.12–79.23
Aura 8 (26.6) 1 (3.3) 0.026*** 1.055 1.23–90.67
Primary headache with aura 8 (30.8) 1 (7.1) 0.124*** 578 0.64–52.03
Mann–Whitney test
GAD Generalized anxiety disorder (patients), TTH tension-type headache
* v
2 test
** Fisher’s exact test
Table 5 Headache characteristics
Headache characteristic GAD (n = 26) Controls (n = 14) P
Frequency (days per month), mean ± SD (range) 9.3 ± 9.5 (1–30) 2.0 ± 2.0 (0.3–6) 0.001**
Intensity (0–10), mean ± SD (range) 5.6 ± 2.2 (2–10) 3.9 ± 2.4 (2–8) 0.049**
Duration (h), mean ± SD (range) 20.2 ± 22.3 (1–72) 4.5 ± 7.6 (0.5–24) 0.004**
GAD generalized anxiety disorder (patients)
** Mann–Whitney test
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123(29.1 ± 68.4 vs. 2.1 ± 0.2; P = 0.019), and that GAD
patients more often made use of health care services for
medical consultations, emergencies or examinations
(12.5 ± 8.1 vs. 2.4 ± 2.6 visits/year; P\0.001).
The GAD patients scored lower in all eight domains of
the SF-36 (i.e., had a poorer quality of life) than did the
controls (Table 7).
Consumption of analgesics was higher in the GAD
patients than in the controls (2.3 ± 3.3 vs. 0.5 ± 1.2 tab-
lets per week; P = 0.031). In terms of the excessive use of
analgesics (for more than 15 days), there was no difference
between GAD patients and controls (16.7 vs. 3.3%;
P = 0.645).
The GAD group presented lower caffeine consumption
than did the control group (244.14 ± 340.68 vs. 380.74 ±
442.59 mg/day; P = 0.042). Excessive consumption of
caffeine ([200 mg/day) was more common in the control
group than in the GAD group (40 vs. 66.67%; P = 0.05).
Of the GAD patients evaluated, 96.6% were diagnosed
with at least one psychiatric comorbidity: principally
another anxiety disorder (83.33%) or depression (43.33%).
In relation to migraine characteristics, migraine duration
presented a positive correlation with the Hamilton Anxiety
Rating Scale score and a negative correlation with the score
in the vitality domain of the SF-36 (the longer the migraine
lasted, the more anxiety symptoms the individual presented
and the poorer the quality of life was in terms of vitality).
In addition, migraine frequency presented a positive cor-
relation with more frequent use of health care services.
In relation to the progression of GAD, the average age at
onsetofepisodicmigrainewashigherintheGADgroupthan
in the control group (30.7 ± 14.8 vs. 13 ± 6.8 years;
Table 6 Symptomatology
Instrument GAD (n = 30) Controls (n = 30) P
HAM-A score, mean ± SD (range) 22.1 ± 6.1 (10–34) 2.4 ± 2.4 (0–8) \0.001*
HAM-D score, mean ± SD (range) 13.7 ± 6.4 (6–28) 1.5 ± 2.5 (0–11) \0.001*
ESS score, mean ± SD (range) 7.3 ± 6.7 (0–21) 4.2 ± 3.7 (0–14) NS*
ESS score C 10, n (%) 11 (36.7) 2 (6.7) 0.004**
ESS score\10, n (%) 19 (63.3) 28 (93.3)
FSS score, mean ± SD (range) 47.6 ± 14.9 (9–56) 13.6 ± 14.9 (9–35) \0.001*
FSS score[27, n (%) 19 (63.3) 1 (3.3) 0.001**
FSS score\27, n (%) 11 (36.7) 29 (96.7)
CFS score, mean ± SD (range) 22.9 ± 7.2 (12–34) 3.5 ± 4.5 (1–19) \0.001*
VAS-F score, mean ± SD (range) 22.1 ± 31.6 (0–100) 15.0 ± 31.6 (0–70) \0.001*
GAD generalized anxiety disorder (patients), HAM-A Hamilton anxiety scale (0–56 points), HAM-D Hamilton depression scale (0–50 points),
ESS Epworth sleepiness scale (0–24 points), FSS fatigue severity scale (9–63 points), CFS Chalder fatigue scale (0–11 points), VAS-F visual
analog scale for fatigue (0–100 points)
* Mann–Whitney test
** v
2 test
Table 7 Medical and social consequences of headache
Variable GAD Controls P
MIDAS score, mean ± SD (range) 29.1 ± 68.4 (0–260) 2.1 ± 0.2 (0–3) 0.019**
Use of healthcare services, mean ± SD (range) 12.5 ± 8.1 (0–33) 2.4 ± 2.6 (0–9) \0.001**
SF-36 functional capacity domain, mean ± SD (total n) 65.3 ± 25.1 (n = 29) 95.8 ± 5.6 (n = 30) \0.001**
SF-36 physical function domain, mean ± SD (total n) 49.1 ± 41.4 (n = 29) 97.5 ± 7.6 (n = 30) \0.001**
SF-36 bodily pain domain, mean ± SD (total n) 64.1 ± 20.7 (n = 29) 88.8 ± 18.8 (n = 30) \0.001**
SF-36 general health domain, mean ± SD (total n) 72.1 ± 21.2 (n = 29) 92.4 ± 10.6 (n = 30) \0.001**
SF-36 vitality domain, mean ± SD (total n) 43.4 ± 21.7 (n = 29) 82.0 ± 13.6 (n = 30) \0.001**
SF-36 social function domain, mean ± SD (total n) 56.0 ± 31.1 (n = 29) 96.7 ± 7.9 (n = 30) \0.001**
SF-36 emotional function domain, mean ± SD (total n) 44.8 ± 44.8 (n = 29) 97.8 ± 12.2 (n = 30) \0.001**
SF-36 mental health domain, mean ± SD (total n) 42.2 ± 22.5 (n = 29) 85.2 ± 14.1 (n = 30) \0.001**
GAD generalized anxiety disorder (patients), MIDAS migraine disability assessment, SF-36 36-item short-form health survey
* Mann–Whitney test
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123P = 0.035).ConsideringonlyGAD patients diagnosed with
primary headache, the onset of GAD preceded that of epi-
sodic migraine in60%(20.1 ± 13.7 vs.31.5 ± 14.4 years).
Theaverageageatonsetofmooddisorderwascomparableto
that of episodic migraine (31.5 ± 14.4 vs. 32.3 ± 13.3;
P = NS).Ofthesampleasawhole,43.3%presentedatriple
diagnosis: GAD, primary headaches (principally migraine)
and depression.
Patients were treated mainly with SSRIs (escitalopram,
citalopram), SNRIs (venlafaxine, duloxetine) combined
with neuromodulators (topiramate 25–150 mg, divalproate
500–2,000 mg). Patients with sleep problems were
administered melatonin 3–12 mg 30 min before bedtime.
Tryciclics antidepressants when tolerated were also used.
Data about psychopharmachological therapies was inclu-
ded; however, since it was not the main aspect of the
research, we could not assess follow-up results and proper
clinical endpoints.
Discussion
There is a lack of data in the literature regarding the
prevalence of primary headaches in GAD patients. How-
ever, many studies have shown that migraine patients are at
increased risk for affective and anxiety disorders [10, 11,
24, 25].
TheprimaryﬁndingofthepresentstudywasthattheGAD
patients differed from the controls in terms of the frequency
of migraine headaches but not in terms of the frequency of
TTH.Thisﬁndingisinagreementwiththeresultsofprevious
studies [10, 11] of affective disorders, in which it has been
suggested that there is a distinct and bidirectional relation-
shipbetweenaffectivedisordersandmigraine,arelationship
that does not exist (or is at best unclear) between affective
disorders and TTH. The comorbidity between affective
disorders and GAD is generally high, and it therefore would
notbesurprisingtoﬁndadistinctrelationshipbetweenGAD
and migraine. This might indicate that there is some basic
biological disturbance underpinning the interrelationships
among depression, anxiety and migraine.
Given the fact that the depression scores were quite high
among the GAD patients evaluated in the present study, the
data obtained could be interpreted to mean that the GAD
patients with migraine were indeed those patients with
chronic affective disorders. In fact, this seems not to be the
case, since the SCID-1/P interview results indicate that
56.67% of the GAD patients did not suffer from depres-
sion, and 43.33% presented major depressive episodes.
Comorbidity between primary headaches and GAD
increases the severity of both conditions. The characteristics
of primary headache episodes worsened more often in GAD
patientsthanincontrols.Theseverityofsymptoms(anxiety,
depression, daytime sleepiness and fatigue), as well as the
medical and social consequences (functional incapacity,
greater use of health care services and lowered quality of
life),werealsomoreexacerbatedintheGADpatientsthanin
the controls. Other authors have found high headache fre-
quency to be associated with a history of panic disorder [25,
26]. In another study, depression and anxiety disorders were
associatedwithbothmigraineandnonmigrainousheadache,
and this association seems more dependent on headache
frequency than on diagnostic category [27]. In a general
populationstudy,itwasfoundthat59%hadheadacheswitha
frequency of 1–4 attacks per month [28, 29]. A nationwide
study in France showed that 56% of individuals experienced
headaches lasting from 2 to 12 h [29], and that 58–85% had
headaches of strong or very strong intensity [29]. In a study
of the prevalence and indirect costs of headache in a Bra-
zilian company, the mean frequency of headache was
4.3 ± 7.0 attacks per month, and the mean headache dura-
tion was 12.2 ± 21.4 h [30].
Among our GAD patients, the perception of pain
intensity during migraine attacks was similar to that found
in the literature using the same instruments [28, 30].
However, in the assessment of an extremely subjective
phenomenon, methodological bias cannot be ruled out.
This difference may be due only to observed differences in
the severity of headaches.
We found that comorbidity with primary headaches had
a negative impact on several measures of symptom severity
and quality of life in individuals with GAD. Our results
indicate severe functional disability and a marked personal
burden (anxiety, depressive symptoms, fatigue and exces-
sive daytime sleepiness), as well as medical and social
consequences (functional incapacity, greater use of
healthcare services and lowered quality of life), in patients
with primary headache and concomitant GAD.
The consumption of analgesics was greater in the GAD
patients with primary headache than in the controls with
primary headache. This ﬁnding is also in accordance with
those of other studies [31]. The ingestion of analgesics can
occur prior to the onset of a headache, due to anxiety and
excessive worrying, which are characteristic of GAD.
Ferrari [32] appraised reasons patients gave for this
behavior: 67% reported difﬁculty in coping with the pain,
62% feared its emergence, and 45% consumed analgesics
to reduce anxiety.
Another possibility is that of higher caffeine consump-
tion rebound headaches [33] and generalized anxiety in
GAD patients. However, caffeine consumption was higher
in the controls.
In individuals presenting more symptoms of anxiety,
migraines lasted longer, lending credence to the hypotheses
that GAD patients create an attention bias for headaches,
and this heightened perception can effectively lengthen the
336 J Headache Pain (2011) 12:331–338
123duration of the headaches. In addition, individuals experi-
encing migraines more frequently also make more frequent
use of health care services, which is also related to
excessive, difﬁcult to control worrying, which is typical of
GAD. World Health Organization data suggest that GAD is
the most common anxiety disorder in primary care.
Our ﬁnding that 96.6% of GAD patients were diagnosed
with at least one psychiatric comorbidity—principally
anotheranxietydisorder(83.33%)ordepression(43.33%)—
is in accordance with the literature, which indicates that
untreatedGADleadstolong-termcomplications,suchasthe
development of major depressive disorder [34, 35].
Disease progression
In terms of age at onset, GAD preceded episodic migraines.
The onset of episodic migraine age tended to occur late in
the GAD group than in the controls, suggesting that
migraines are a long-term consequence of untreated GAD.
Nearly half (43.3%) of our patients presented a triple
diagnosis: GAD, primary headaches and depression.
These ﬁndings are consistent with the progressive disor-
der model proposed by Merikangas et al. [11], in which
anxiety disorders generally precede migraine, which is then
followed by depression. The authors postulated that there is
‘‘a syndromic relationship between migraine, anxiety and
depression’’,aspectrumofsymptomsinitiatingwithanxiety
(frequently in early infancy), followed by the occurrence of
migraines and subsequent depressive episodes in adulthood.
The fact that, in the present study, the onset of episodic
migraines tended to occur later in the GAD patients than in
the controls might indicate that the headaches experienced
by GAD patients were secondary to anxiety.
Comorbidity
Longitudinal studies have shown a speciﬁc bidirectional
association between migraine and depression, suggesting a
common etiology. There are no deﬁnitive data that explain
the association between GAD and migraine. Environmental
or genetic risk factors might produce a brain state that
predisposes to both conditions, i.e., there might be some
common biology underlying the two conditions [36]. There
appears to be an association between migraine and affec-
tive disorders, particularly depression and anxiety.
Migraine and other primary headaches heighten the risk of
onset/aggravation of GAD, whereas GAD heightens the
risk of onset of migraine and other primary headaches. The
latter effect seems to be more consistent, since the onset of
GAD occurs at an earlier age than does that of episodic
migraine.
The apparently distinct and bidirectional relationship
that we found between affective disorders and migraine, a
relationship that does not exist (or is at best unclear)
between affective disorders and TTH, is in line with the
results of previous studies analyzing affective disorders.
The comorbidity between affective disorders and GAD is
generally high, and it therefore would not be surprising to
ﬁnd a distinct relationship between GAD and migraine.
This might indicate that there is some basic biological
disturbance underpinning the interrelationships among
depression, anxiety and migraine.
A recent paper [37] was published looking at 206 con-
secutive outpatients in an anxiety disorders clinic sample,
the prevalence of migraine was 67%. The severity of anx-
iety disorder symptoms was signiﬁcantly higher in patients
with migraine compared with patients without migraine.
Limitations
The present study had some methodological limitations.
The small sample size (n = 30) and the especially small
number of males (n = 7) in the GAD sample create a
number of problems: lack of statistical power can lead to
the false conclusion that differences in some variables do
not exist (Type II error), whereas the performance of a
number of statistical tests that is greater than the number of
subjects in a group (without correction for the number of
tests) can lead to chance ﬁndings (Type I error). However,
in observing GAD group migraine frequency, we found no
gender-related differences in terms of diagnoses of primary
headache, headache or TTH. The small number of males
limits the ability to test for gender-related differences,
which might exist for some variables.
Another limitation of the study was the fact that the
control group was composed not of ‘normal’ individuals
(general population) but of ‘supernormal’ individuals
(proven to be free of psychiatric disorders). In addition, the
appraiser could not be blinded as to the presence or absence
of a psychiatric diagnosis, since symptoms were reported
during the neurological interview.
Finally, there was the limitation in relation to causality.
Further longitudinal studies could provide more informa-
tion on the course and progression of GAD.
Conclusion
Strengths of this manuscript include the reporting of data
for a carefully diagnosed sample of patients with GAD and
the use of standardized, validated methods of assessing
psychiatric diagnosis and psychiatric symptoms.
Our results indicate that the high prevalence of primary
headaches in GAD patients has a signiﬁcant impact on the
J Headache Pain (2011) 12:331–338 337
123lives of those patients and on the health care system.
Diagnosing primary headache is important in patients with
anxiety disorders, particularly those with GAD, since cor-
rect assessment can lead to better patient management and
more favorable clinical outcomes.
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